|
Synonyms: ADX-324 | ADX324
Compound class:
Nucleic acid
Comment: Onvuzosiran (ADX-324) is a GalNAc-conjugated small interfering RNA (siRNA) that is proposed to reduce prekallikrein (PKK) expression at the mRNA level. GalNAc conjugation is used to promote targeted hepatic delivery. in the nucleotide sequences provided here (reproduced from the INN record) the GalNAc sugar is attached at the R1 position. The nucleotides are chemically modified (2'-O-methylnucleotides/2'-MOE and 2'-deoxy-2'-fluoronucleotide/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, to improve RNA binding and pharmacokinetics.
|
| No information available. |
Summary of Clinical Use ![]() |
| Onvuzosiran (ADX-324) was progressed as a clinical candidate to evaluate it as a potential treatment for hereditary angioedema (HAE) [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07428499 | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | Phase 3 Interventional | ADARx Pharmaceuticals, Inc. | ||
| NCT06960213 | STOP-HAE: A Phase 3 Study of ADX-324 in HAE | Phase 3 Interventional | ADARx Pharmaceuticals, Inc. | ||
| NCT05691361 | Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients | Phase 1/Phase 2 Interventional | ADARx Pharmaceuticals, Inc. | ||